The 4 Most Important Things to Know About Merck's Q4 Earnings Results

Merck (NYSE: MRK) is off to a rocky start in 2020. The company's blockbuster cancer drug, Keytruda, disappointed in a late-stage clinical study targeting small cell lung cancer. Shortly afterward, Chinese biotech BeiGene announced positive results from a late-stage study for tislelizumab, potentially setting up a battle between the drug and Keytruda in the big Chinese market.